Skip to main content
Venous thromboembolism in patients with diabetes mellitus
Quantitative Health Sciences Publications and Presentations
  • Gregory Piazza, Harvard Medical School
  • Samuel Z. Goldhaber, Harvard Medical School
  • Aimee Kroll, University of Massachusetts Medical School
  • Robert J. Goldberg, University of Massachusetts Medical School
  • Catherine Emery, University of Massachusetts Medical School
  • Frederick A. Spencer, University of Massachusetts Medical School
UMMS Affiliation
Department of Medicine, Division of Cardiovascular Medicine; Department of Quantitative Health Sciences; Meyers Primary Care Institute
Publication Date
Document Type
Adult; Aged; Aged, 80 and over; Comorbidity; Diabetes Complications; Female; Humans; Male; Massachusetts; Middle Aged; Risk Factors; Venous Thromboembolism
PURPOSE: The majority of epidemiological studies demonstrate an increased risk of venous thromboembolism among diabetic patients. Our aim was to compare clinical characteristics, prophylaxis, treatment, and outcomes of venous thromboembolism in patients with and without previously diagnosed diabetes. METHODS: We studied diabetic patients in the population-based Worcester Venous Thromboembolism Study of 2488 consecutive patients with validated venous thromboembolism. RESULTS: Of 2488 venous thromboembolism patients, 476 (19.1%) had a clinical history of diabetes. Thromboprophylaxis was omitted in more than one third of diabetic patients who had been hospitalized for non-venous-thromboembolism-related illness or had undergone major surgery within 3 months before diagnosis. Patients with diabetes were more likely than nondiabetic patients to have a complicated course after venous thromboembolism. Patients with diabetes were more likely than patients without diabetes to suffer recurrent deep vein thrombosis (14.9% vs 10.7%) and long-term major bleeding complications (16.4% vs 11.7%) (all P=.01). Diabetes was associated with a significant increase in the risk of recurrent deep vein thrombosis (adjusted odds ratio [AOR] 1.74; 95% confidence interval [CI], 1.21-2.51). Aspirin therapy at discharge (AOR 1.59; 95% CI, 1.1-2.3) and chronic kidney disease (AOR 2.19; 95% CI, 1.44-3.35) were independent predictors of long-term major bleeding. CONCLUSION: Patients with diabetes who developed venous thromboembolism were more likely to suffer a complicated clinical course. Diabetes was an independent predictor of recurrent deep vein thrombosis. We observed a low rate of thromboprophylaxis in diabetic patients. Further studies should focus on venous thromboembolism prevention in this vulnerable population.
DOI of Published Version
Am J Med. 2012 Jul;125(7):709-16. Epub 2012 May 3. Link to article on publisher's site
PubMed ID
Related Resources
Link to Article in PubMed
Citation Information
Gregory Piazza, Samuel Z. Goldhaber, Aimee Kroll, Robert J. Goldberg, et al.. "Venous thromboembolism in patients with diabetes mellitus" Vol. 125 Iss. 7 (2012) ISSN: 0002-9343 (Linking)
Available at: